Tectonic Therapeutic (TECX) Competitors $29.12 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$29.16 +0.04 (+0.14%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. HCM, ADPT, AUPH, BHC, and ADMAShould you buy Tectonic Therapeutic stock or one of its competitors? MarketBeat compares Tectonic Therapeutic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tectonic Therapeutic include HUTCHMED (HCM), Adaptive Biotechnologies (ADPT), Aurinia Pharmaceuticals (AUPH), Bausch Health Cos (BHC), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. TECX vs. HCMTECX vs. ADPTTECX vs. AUPHTECX vs. BHCTECX vs. ADMAHow does Tectonic Therapeutic compare to HUTCHMED?HUTCHMED (NASDAQ:HCM) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Do institutionals & insiders have more ownership in HCM or TECX? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, HCM or TECX? HUTCHMED has higher revenue and earnings than Tectonic Therapeutic. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$548.51M3.81$456.91MN/AN/ATectonic TherapeuticN/AN/A-$74.15M-$4.46N/A Is HCM or TECX more profitable? HUTCHMED's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Tectonic Therapeutic N/A -32.33%-30.92% Does the media refer more to HCM or TECX? In the previous week, HUTCHMED had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for HUTCHMED and 2 mentions for Tectonic Therapeutic. HUTCHMED's average media sentiment score of 0.20 beat Tectonic Therapeutic's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate HCM or TECX? HUTCHMED presently has a consensus price target of $16.88, indicating a potential upside of 40.74%. Tectonic Therapeutic has a consensus price target of $79.83, indicating a potential upside of 174.15%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more risk and volatility, HCM or TECX? HUTCHMED has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.27, meaning that its stock price is 227% more volatile than the broader market. SummaryHUTCHMED and Tectonic Therapeutic tied by winning 6 of the 12 factors compared between the two stocks.How does Tectonic Therapeutic compare to Adaptive Biotechnologies?Tectonic Therapeutic (NASDAQ:TECX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Do analysts rate TECX or ADPT? Tectonic Therapeutic currently has a consensus price target of $79.83, suggesting a potential upside of 174.15%. Adaptive Biotechnologies has a consensus price target of $19.57, suggesting a potential upside of 41.00%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts plainly believe Tectonic Therapeutic is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Adaptive Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Which has more risk & volatility, TECX or ADPT? Tectonic Therapeutic has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Which has better earnings and valuation, TECX or ADPT? Adaptive Biotechnologies has higher revenue and earnings than Tectonic Therapeutic. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$74.15M-$4.46N/AAdaptive Biotechnologies$276.98M8.02-$59.50M-$0.33N/A Does the media favor TECX or ADPT? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Adaptive Biotechnologies and 2 mentions for Tectonic Therapeutic. Adaptive Biotechnologies' average media sentiment score of 0.72 beat Tectonic Therapeutic's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TECX or ADPT more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Tectonic Therapeutic's return on equity of -32.33% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -32.33% -30.92% Adaptive Biotechnologies -16.82%-40.06%-16.64% Do insiders & institutionals have more ownership in TECX or ADPT? 62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryTectonic Therapeutic and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?Aurinia Pharmaceuticals (NASDAQ:AUPH) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation. Does the media favor AUPH or TECX? In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 2 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.06 beat Tectonic Therapeutic's score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AUPH or TECX? Aurinia Pharmaceuticals currently has a consensus price target of $17.25, suggesting a potential upside of 13.34%. Tectonic Therapeutic has a consensus price target of $79.83, suggesting a potential upside of 174.15%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is AUPH or TECX more profitable? Aurinia Pharmaceuticals has a net margin of 99.97% compared to Tectonic Therapeutic's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals99.97% 26.62% 19.65% Tectonic Therapeutic N/A -32.33%-30.92% Do insiders and institutionals have more ownership in AUPH or TECX? 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, AUPH or TECX? Aurinia Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$283.05M6.92$287.20M$2.177.01Tectonic TherapeuticN/AN/A-$74.15M-$4.46N/A Which has more risk & volatility, AUPH or TECX? Aurinia Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.27, indicating that its stock price is 227% more volatile than the broader market. SummaryAurinia Pharmaceuticals beats Tectonic Therapeutic on 8 of the 15 factors compared between the two stocks.How does Tectonic Therapeutic compare to Bausch Health Cos?Tectonic Therapeutic (NASDAQ:TECX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Does the media refer more to TECX or BHC? In the previous week, Bausch Health Cos had 19 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 21 mentions for Bausch Health Cos and 2 mentions for Tectonic Therapeutic. Bausch Health Cos' average media sentiment score of 0.03 beat Tectonic Therapeutic's score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TECX or BHC more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Tectonic Therapeutic's return on equity of -32.33% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -32.33% -30.92% Bausch Health Cos -11.47%-2,922.77%5.63% Do analysts recommend TECX or BHC? Tectonic Therapeutic currently has a consensus target price of $79.83, suggesting a potential upside of 174.15%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 46.39%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Bausch Health Cos 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Do institutionals & insiders hold more shares of TECX or BHC? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, TECX or BHC? Bausch Health Cos has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$74.15M-$4.46N/ABausch Health Cos$10.27B0.20$157M-$3.24N/A Which has more risk and volatility, TECX or BHC? Tectonic Therapeutic has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. SummaryTectonic Therapeutic and Bausch Health Cos tied by winning 8 of the 16 factors compared between the two stocks.How does Tectonic Therapeutic compare to ADMA Biologics?Tectonic Therapeutic (NASDAQ:TECX) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do analysts prefer TECX or ADMA? Tectonic Therapeutic presently has a consensus target price of $79.83, indicating a potential upside of 174.15%. ADMA Biologics has a consensus target price of $19.00, indicating a potential upside of 130.58%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86ADMA Biologics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility and risk, TECX or ADMA? Tectonic Therapeutic has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Do insiders & institutionals believe in TECX or ADMA? 62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer TECX or ADMA? In the previous week, ADMA Biologics had 8 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for ADMA Biologics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.00 beat ADMA Biologics' score of -0.13 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TECX or ADMA more profitable? ADMA Biologics has a net margin of 32.43% compared to Tectonic Therapeutic's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -32.33% -30.92% ADMA Biologics 32.43%39.98%28.08% Which has better earnings & valuation, TECX or ADMA? ADMA Biologics has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$74.15M-$4.46N/AADMA Biologics$510.17M3.74$146.93M$0.6812.12 SummaryADMA Biologics beats Tectonic Therapeutic on 9 of the 16 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition ExportMetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$549.47M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-6.5318.7421.2225.65Price / SalesN/A323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book2.387.0910.377.14Net Income-$74.15M$24.45M$3.57B$335.98M7 Day Performance5.13%5.45%6.01%3.56%1 Month Performance2.03%2.43%3.52%2.54%1 Year Performance34.50%62.98%34.13%35.05% Tectonic Therapeutic Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic1.6717 of 5 stars$29.12flat$79.83+174.2%+34.5%$549.47MN/AN/A120HCMHUTCHMED3.7948 of 5 stars$12.06+0.9%$16.88+39.9%-10.5%$2.08B$548.51MN/A1,796ADPTAdaptive Biotechnologies3.7921 of 5 stars$12.96+2.0%$19.57+51.0%+55.4%$2.03B$276.98MN/A790AUPHAurinia Pharmaceuticals3.0666 of 5 stars$15.55-0.3%$17.25+10.9%+88.4%$2.01B$283.05M7.17300Positive NewsGap UpBHCBausch Health Cos2.8939 of 5 stars$5.32-0.5%$8.00+50.5%+22.7%$2.00B$10.27BN/A20,300 Related Companies and Tools Related Companies HUTCHMED Competitors Adaptive Biotechnologies Competitors Aurinia Pharmaceuticals Competitors Bausch Health Cos Competitors ADMA Biologics Competitors Trevi Therapeutics Competitors Mesoblast Competitors Pharvaris Competitors Ocular Therapeutix Competitors Stoke Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
